M
Mid Atlantic Retina | Bethlehem, PA
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
APL-2
Pegcetacoplan
CU06-1004
Bromfenac
Eplerenone
Tarcocimab
Parent organization
This site is a part of Mid Atlantic Retina
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 9 total trials
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment
Enrolling
Neovascular (Wet) Age-Related Macular Degeneration
Biological: 4D-150 IVT
Biological: Aflibercept IVT
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.
Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...
Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)
Trial sponsors
A
W
4
C
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems